Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid Stoffw Microb

Terbuch, A; Absenger, G.
Neoadjuvant treatment in non-small-cell lung cancer-the earlier, the better
MEMO-MAG EUR MED ONC. 2022; Doi: 10.1007/s12254-022-00828-3
Web of Science FullText FullText_MUG

 

Führende Autor*innen der Med Uni Graz

Terbuch Angelika

Co-Autor*innen der Med Uni Graz

Absenger Gudrun

Altmetrics:

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

Abstract:

Neoadjuvant checkpoint inhibition in resectable non-small-cell lung cancer (NSCLC) is safe and high major pathologic response (MPR) and pathologic complete response (pCR) rates can be achieved in combination with chemotherapy. The Checkmate 816 trial gives evidence that pathologic response also leads to EFS benefit. This opens new opportunities in the curative setting but also raises questions: What is the value of adjuvant treatment with checkpoint inhibitors? Or should we treat our patients peri-operatively? Which biomarkers can we use for treatment decisions and monitoring of curative patients? Targeted therapies in the neoadjuvant setting lead to promising response rates and data for EFS and overall survival are eagerly awaited.

Find related publications in this database (Keywords)

Neoadjuvant treatment

Pathologic complete response

Major pathologic response

Prognosis

Biomarker

© Med Uni Graz • Impressum